Hypofractionation as a solution to radiotherapy access in latin america: expert perspective.
Latin America
access
cancer care
hypofractionated radiotherapy
oncology
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
08
2022
accepted:
24
10
2022
entrez:
12
1
2023
pubmed:
13
1
2023
medline:
13
1
2023
Statut:
epublish
Résumé
Limited radiation therapy resources have resulted in an interest in developing time and cost-saving innovations to expand access to cancer treatment, in Latin America. Therefore, hypofractionated radiotherapy (HRT) is a possible solution, as this modality delivers radiation over a shorter period of time. A selected panel of Latin American (LA) experts in fields related to HRT were provided with a series of relevant questions to address, prior to the multi-day conference. Within this meeting, each narrative was discussed and edited, through numerous rounds of discussion, until agreement was achieved. The challenges identified in increasing the adoption of HRT in LA include a lack of national and regional clinical practice guidelines and cancer registries; a lack of qualified human resources and personnel education; high up-front costs of equipment; disparate resource distribution and scarce HRT research. An analysis for these overarching challenges was developed and answered with recommendations. Extending the adoption of HRT in LA can provide a path forward to increase access to radiotherapy and overcome the shortage of equipment. HRT has the potential to improve population health outcomes and patient centered care, while offering comparable local control, toxicity, palliation, and late effects for multiple indications, when compared to conventional RT. Concerted efforts from all involved stakeholders are needed to overcome the barriers in adopting this strategy in LA countries. The recommendations presented in this article can serve as a plan of action for HRT adoption in other countries in a similar situation.
Sections du résumé
Background
UNASSIGNED
Limited radiation therapy resources have resulted in an interest in developing time and cost-saving innovations to expand access to cancer treatment, in Latin America. Therefore, hypofractionated radiotherapy (HRT) is a possible solution, as this modality delivers radiation over a shorter period of time.
Materials and methods
UNASSIGNED
A selected panel of Latin American (LA) experts in fields related to HRT were provided with a series of relevant questions to address, prior to the multi-day conference. Within this meeting, each narrative was discussed and edited, through numerous rounds of discussion, until agreement was achieved.
Results
UNASSIGNED
The challenges identified in increasing the adoption of HRT in LA include a lack of national and regional clinical practice guidelines and cancer registries; a lack of qualified human resources and personnel education; high up-front costs of equipment; disparate resource distribution and scarce HRT research. An analysis for these overarching challenges was developed and answered with recommendations.
Conclusion
UNASSIGNED
Extending the adoption of HRT in LA can provide a path forward to increase access to radiotherapy and overcome the shortage of equipment. HRT has the potential to improve population health outcomes and patient centered care, while offering comparable local control, toxicity, palliation, and late effects for multiple indications, when compared to conventional RT. Concerted efforts from all involved stakeholders are needed to overcome the barriers in adopting this strategy in LA countries. The recommendations presented in this article can serve as a plan of action for HRT adoption in other countries in a similar situation.
Identifiants
pubmed: 36632306
doi: 10.5603/RPOR.a2022.0108
pii: rpor-27-6-1094
pmc: PMC9826647
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1094-1105Informations de copyright
© 2022 Greater Poland Cancer Centre.
Déclaration de conflit d'intérêts
Conflicts of interest The co-authors declare no conflicts of interest.
Références
Eur J Cancer. 2014 Nov;50(17):2939-49
pubmed: 25304298
Radiother Oncol. 2021 Jul;160:236-239
pubmed: 33992629
Int J Radiat Oncol Biol Phys. 2020 Oct 1;108(2):390-393
pubmed: 32890517
Lancet Oncol. 2019 Feb;20(2):e112-e123
pubmed: 30712798
Lancet. 2006 Sep 2;368(9538):843-54
pubmed: 16950362
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Clin Oncol (R Coll Radiol). 2017 Feb;29(2):72-83
pubmed: 27916340
Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):485-494
pubmed: 33007435
Radiother Oncol. 2012 Jan;102(1):148-53
pubmed: 21872955
Curr Urol Rep. 2019 Jul 29;20(9):53
pubmed: 31359187
JCO Glob Oncol. 2020 Apr;6:667-678
pubmed: 32343628
Pract Radiat Oncol. 2020 Nov - Dec;10(6):e452-e460
pubmed: 32171852
Lancet Oncol. 2021 Nov;22(11):e474-e487
pubmed: 34735817
J Clin Oncol. 2015 Dec 10;33(35):4145-50
pubmed: 26392096
Breast. 2010 Jun;19(3):192-7
pubmed: 20511069
Lancet Oncol. 2015 Jun;16(6):630-7
pubmed: 25981812
JAMA. 2006 Jun 7;295(21):2483-91
pubmed: 16757720
Lancet. 2020 May 23;395(10237):1613-1626
pubmed: 32580883
Cochrane Database Syst Rev. 2008 Jul 16;(3):CD003860
pubmed: 18646095
J Med Radiat Sci. 2018 Jun;65(2):148-157
pubmed: 29532613
Oncology (Williston Park). 2017 Apr 15;31(4):248-54
pubmed: 28412775
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Radiother Oncol. 2020 Jul;148:213-215
pubmed: 32342861
Breast Cancer Res Treat. 2019 Jun;175(3):531-545
pubmed: 30929116
Clin Oncol (R Coll Radiol). 2015 Jul;27(7):420-6
pubmed: 25752244
Lancet Oncol. 2015 Sep;16(10):1153-86
pubmed: 26419354
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1017-24
pubmed: 25220719
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Clin Orthop Relat Res. 2021 Nov 1;479(11):2430-2443
pubmed: 33942797
J Clin Oncol. 2020 May 20;38(15):1676-1684
pubmed: 32119599
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1414-1428
pubmed: 27479724
J Med Imaging Radiat Sci. 2012 Mar;43(1):38-42
pubmed: 31052018
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):182-95
pubmed: 25835624
Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):68-80
pubmed: 33891979
J Oncol Pract. 2017 Apr;13(4):e283-e290
pubmed: 28291382
Nat Rev Urol. 2017 Jun 30;14(7):415-439
pubmed: 28664931
Radiother Oncol. 2021 Apr;157:32-39
pubmed: 33453312
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1142-1150
pubmed: 33714525
Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):522-31
pubmed: 11872300
J Med Ethics. 2018 Mar;44(3):171-173
pubmed: 28780524
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):287-295
pubmed: 27986343
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):428-34
pubmed: 26867870
Lancet Oncol. 2020 Jan;21(1):e42-e54
pubmed: 31908306
Lancet Oncol. 2021 Jan;22(1):29-42
pubmed: 33301740
Clin Oncol (R Coll Radiol). 2017 Feb;29(2):84-92
pubmed: 27939337
Med Phys. 2010 Aug;37(8):4078-101
pubmed: 20879569
J Clin Oncol. 2017 Jun 10;35(17):1884-1890
pubmed: 28296582
Radiother Oncol. 2018 Sep;128(3):400-405
pubmed: 29859755
Lancet Oncol. 2006 Jul;7(7):584-95
pubmed: 16814210
Radiother Oncol. 2005 Apr;75(1):54-63
pubmed: 15878101
J Natl Cancer Inst. 2005 Jun 1;97(11):786-8
pubmed: 15928293
Pract Radiat Oncol. 2011 Apr-Jun;1(2):60-71
pubmed: 25740118
Clin Oncol (R Coll Radiol). 2009 Nov;21(9):659-61
pubmed: 19713088
Am J Clin Oncol. 1988 Jun;11(3):220-52
pubmed: 3289359
Radiother Oncol. 2022 Apr;169:114-123
pubmed: 34461186
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789
pubmed: 30959121
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Phys Med Biol. 2005 Aug 21;50(16):3655-67
pubmed: 16077219